Cidara Completes 5,000-Patient Enrollment in Phase 2b Universal Flu Prevention Trial, Secures $105M Financing
Key Insights
Cidara Therapeutics has completed enrollment of 5,000 subjects in its Phase 2b NAVIGATE trial evaluating CD388, a single-dose universal influenza (search) preventative drug.
The company secured $105 million in private placement funding led by Venrock Healthcare Capital Partners (search), strengthening its financial position for continued drug development.
Due to the severe 2024-25 flu season, Cidara may conduct an early efficacy analysis in the first half of 2025, potentially accelerating the timeline for Phase 3 trials.
Cidara Therapeutics has reached a significant milestone in its influenza (search) prevention program, announcing full enrollment of 5,000 subjects in its Phase 2b NAVIGATE trial evaluating CD388, a novel long-acting universal influenza preventative drug. The trial, conducted across clinical sites in the U.S. and UK, marks a crucial step forward in the company's mission to develop a single-dose seasonal flu prevention solution.
Trial Design and Progress
The randomized, double-blind, controlled study is evaluating three different dose groups of CD388 against placebo, with subjects randomized in a 1:1:1:1 ratio. Participants received their doses at the beginning of the 2024-25 influenza (search) season and will be monitored throughout the season for breakthrough cases. The trial will compare rates of both laboratory and clinically confirmed influenza between treatment and placebo groups.
Strategic Financing Supports Development
In a significant financial development, Cidara secured $105 million through a private placement in November 2024. The funding round was spearheaded by new investor Venrock Healthcare Capital Partners (search), with substantial participation from prominent life sciences investors including RA Capital Management (search), TCGX, and BVF Partners LP. This capital injection strengthens the company's position to advance its clinical programs.
Accelerated Timeline Potential
The severity of the 2024-25 flu season has created an opportunity for potential early analysis of efficacy data in the first half of 2025. This development could accelerate the program's timeline, potentially enabling the initiation of Phase 3 studies during the 2025-26 Northern Hemisphere influenza (search) season.
Technology Platform and Corporate Progress
CD388, developed using Cidara's proprietary Cloudbreak® platform, represents a novel approach to influenza (search) prevention through drug-Fc conjugate (DFC) immunotherapy. The drug candidate received Fast Track Designation from the FDA in June 2023, highlighting its potential significance in addressing unmet medical needs in influenza prevention.
"2024 was a transformational year for Cidara," stated Jeffrey Stein, Ph.D., president and chief executive officer. "Based on our collective achievements and the promising CD388 clinical data generated to date, we believe we are well-positioned to continue advancing CD388 as a potential long-acting, universal influenza (search) preventative."
Financial Position
As of December 31, 2024, Cidara reported a strong financial position with cash and equivalents totaling $196.2 million, compared to $35.8 million at the end of 2023. This substantial increase reflects successful fundraising efforts throughout the year, providing runway for continued development of their clinical programs.
The company has also strengthened its leadership team with the appointment of Frank Karbe as Chief Financial Officer in February 2025, bringing over 25 years of biopharma industry experience to guide the company's financial strategy as it advances toward commercialization.